» Articles » PMID: 16022914

Adrenalectomy for Solitary Adrenal Metastases from Non-small Cell Lung Cancer

Overview
Journal Lung Cancer
Specialty Oncology
Date 2005 Jul 19
PMID 16022914
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The treatment of patients with adrenal metastases from lung cancer (non-small cell lung cancer, NSCLC) remains controversial. Several studies of adrenalectomy in cases of isolated adrenal metastases from NSCLC suggest that these patients could have improved survival. Our aim is to define the history of patients after resection of solitary metastases to the adrenal gland and to identify characteristics of patients who achieved prolonged survival.

Methods: Between January 1997 and July 2000, 11 patients underwent curative resection for metastatic NSCLC of the adrenal gland in our institution. In all patients who were accepted for curative adrenalectomy, the primary NSCLC had been treated by complete resection.

Results: Eleven patients (seven men and four women) with unilateral adrenal metastases of NSCLC entered the study. Median age was 59 years (range 47-67 years). There was no perioperative death. The overall median survival after metastasectomy was 12.6 months (CI: 9.2-16.1 months). Patients with curative resection and metachronous disease (n=6) had a median survival of 30.9 months and tended to do better than patients with synchronous adrenal metastases (n=5) (median survival: 10.3 months).

Conclusions: We conclude that adrenalectomy for clinically solitary, resectable metastases can be performed safely. It appears reasonable that such selected patients should be considered surgical candidates.

Citing Articles

Adrenal Metastasectomy in the Era of Immuno- and Targeted Therapy.

Wachtel H, Dickson P, Fisher S, Kiernan C, Solorzano C Ann Surg Oncol. 2023; 30(7):4146-4155.

PMID: 37079202 DOI: 10.1245/s10434-023-13474-8.


Outcome and prognosis after adrenal metastasectomy: nationwide study.

Vlk E, Ebbehoj A, Donskov F, Poulsen P, Rashu B, Bro L BJS Open. 2022; 6(2).

PMID: 35442402 PMC: 9020450. DOI: 10.1093/bjsopen/zrac047.


Outcomes after Surgical Treatment of Metastatic Disease in the Adrenal Gland; Valuable for the Patient?.

Metman M, Vietor C, Seinen A, Berends A, Hemmer P, Kerstens M Cancers (Basel). 2022; 14(1).

PMID: 35008320 PMC: 8750225. DOI: 10.3390/cancers14010156.


Incidental Adrenal Mass in a Patient With Surgically Treated Lung Adenocarcinoma.

Daprano W, Shroff S, Neychev V Cureus. 2022; 13(11):e19938.

PMID: 34984114 PMC: 8714050. DOI: 10.7759/cureus.19938.


Surgical outcomes of stage IV non-small cell lung cancer: a single-center experience.

Zhang C, Wang L, Li W, Huang Z, Liu W, Bao P J Thorac Dis. 2020; 11(12):5463-5473.

PMID: 32030265 PMC: 6988052. DOI: 10.21037/jtd.2019.11.30.